Akebia Therapeutics, Inc.
AKBA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001517022
No open-market purchases or sales by Akebia Therapeutics, Inc. insiders were filed in the last 90 days; 170 institutions reported holding it in 13F filings for Q2 2026, worth $123.2M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Akebia Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 103
- −9 vs. Q1 2024
- Shares held
- 56.3M
- −679.5K (−1.2%) vs. Q1 2024
- Total value
- $57.4M
- −$46.8M (−44.9%) vs. Q1 2024
- New holders
- 23
- 31 more added
- Sold out
- 32
- 23 more reduced
2 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AKBA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 170 | $123.2M |
| Q1 2026 | 171 | $141.4M |
| Q4 2025 | 166 | $190.4M |
| Q3 2025 | 177 | $337.7M |
| Q2 2025 | 158 | $394.1M |
| Q1 2025 | 143 | $182.7M |
| Q4 2024 | 121 | $128.9M |
| Q3 2024 | 114 | $78.4M |
| Q2 2024 | 103 | $57.4M |
| Q1 2024 | 114 | $104.3M |
| Q4 2023 | 87 | $72.7M |
| Q3 2023 | 76 | $58.0M |
| Q2 2023 | 79 | $46.0M |
| Q1 2023 | 65 | $29.1M |
| Q4 2022 | 75 | $30.2M |
| Q3 2022 | 90 | $16.5M |
| Q2 2022 | 97 | $20.2M |
| Q1 2022 | 124 | $58.3M |
| Q4 2021 | 133 | $218.7M |
| Q3 2021 | 127 | $283.7M |
| Q2 2021 | 139 | $402.4M |
| Q1 2021 | 145 | $340.3M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Akebia Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Satter Management Co., L.P. | 5,747,906 | $5.86M | 11.49% | −7,457,213−56.5% | Reduced |
| Vanguard Group Inc | 9,276,263 | $9.46M | 0.00% | +1,050,291+12.8% | Added |
| BlackRock Inc. | 11,638,484 | $11.9M | 0.00% | +9,099,259+358.3% | Added |
| EAM Investors, LLC | 0 | $0 | 0.00% | −428,549−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −398,247−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −186,232−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −140,925−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −137,742−100.0% | Sold out |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 0 | $0 | 0.00% | −92,554−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −81,676−100.0% | Sold out |
| Omers Administration Corp | 0 | $0 | 0.00% | −77,000−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −68,475−100.0% | Sold out |
| CTC Alternative Strategies, Ltd. | 0 | $0 | 0.00% | −58,700−100.0% | Sold out |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −47,100−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −44,678−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −43,545−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −41,920−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −32,073−100.0% | Sold out |
| Cannon Global Investment Management, LLC | 0 | $0 | 0.00% | −28,000−100.0% | Sold out |
| Polymer Capital Management (HK) LTD | 0 | $0 | 0.00% | −23,900−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −22,500−100.0% | Sold out |
| Oxford Asset Management LLP | 0 | $0 | 0.00% | −22,262−100.0% | Sold out |
| DRW Securities, LLC | 0 | $0 | 0.00% | −21,000−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −20,678−100.0% | Sold out |
| TradeLink Capital LLC | 0 | $0 | 0.00% | −13,200−100.0% | Sold out |
| Symmetry Investments LP | 0 | $0 | 0.00% | −12,400−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −10,900−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −10,590−100.0% | Sold out |
| Grimes & Company, Inc. | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Ameritas Advisory Services, LLC | 0 | $0 | 0.00% | −12,096−100.0% | Sold out |
| Guggenheim Capital LLC | 0 | $0 | 0.00% | −1,039−100.0% | Sold out |
| Truvestments Capital LLC | 0 | $0 | 0.00% | −756−100.0% | Sold out |
| NBC Securities, Inc. | 0 | $0 | 0.00% | −690−100.0% | Sold out |
| Hexagon Capital Partners LLC | 0 | $0 | 0.00% | −186−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −9,170−100.0% | Sold out |
| CWA Asset Management Group, LLC | – | – | – | – | Not filed |
| Eudaimonia Partners, LLC | – | – | – | – | Not filed |